Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2019 Oct 25

PMID 31645095

Citations 8

Authors

Yeseul Kim

Seong Sik Bang

Seungyun Jee

Sungeon Park

Su-Jin Shin

Kiseok Jang

Affiliations

Soon will be listed here.

Abstract

Purpose: Mesenchymal epithelial transition (MET) is a proto-oncogene that encodes a heterodimeric transmembrane receptor tyrosine kinase for the hepatocyte growth factor. Aberrant MET signaling has been described in several solid tumors-especially non-small cell lung cancer- and is associated with tumor progression and adverse prognosis. As MET is a potential therapeutic target, information regarding its prevalence and clinicopathological relevance is crucial.

Materials And Methods: We investigated MET expression and gene amplification in 113 gallbladder cancers using tissue microarray. Immunohistochemistry was used to evaluate MET overexpression, and silver/fluorescence in situ hybridization (ISH) was used to assess gene copy number.

Results: MET overexpression was found in 37 cases of gallbladder carcinoma (39.8%), and gene amplification was present in 17 cases (18.3%). MET protein expression did not correlate with MET amplification. MET amplification was significantly associated with aggressive clinicopathological features, including high histological grade, advanced pT category, lymph node metastasis, and advanced American Joint Committee on Cancer stage. There was no significant correlation between any clinicopathological factors and MET overexpression. No difference in survival was found with respect to MET overexpression and amplification status.

Conclusion: Our data suggested that MET might be a potential therapeutic target for targeted therapy in gallbladder cancer, because MET amplification was found in a subset of tumors associated with adverse prognostic factors. Detection of MET amplification by ISH might be a useful predictive biomarker test for anti-MET therapy.

Citing Articles

Structure based multi-targeted screening, docking, DFT and simulation of anticancer natural compounds against gallbladder cancer.

Singh S, Yadav J, Singh S, Sahu S, Puneet P, Singh R In Silico Pharmacol. 2025; 13(1):39.

PMID: 40061629 PMC: 11885705. DOI: 10.1007/s40203-025-00326-4.

Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer.

Yu Q, Fu P, Zhang C, Li L, Huang W World J Gastrointest Surg. 2024; 16(5):1395-1406.

PMID: 38817281 PMC: 11135301. DOI: 10.4240/wjgs.v16.i5.1395.

EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.

Kim Y, Jee S, Kim H, Paik S, Choi D, Yoo S Oncologist. 2024; 29(8):e1051-e1060.

PMID: 38709907 PMC: 11299936. DOI: 10.1093/oncolo/oyae076.

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.

Yuan P, Xue X, Qiu T, Ying J Ther Adv Med Oncol. 2024; 16:17588359231221910.

PMID: 38249331 PMC: 10798113. DOI: 10.1177/17588359231221910.

A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification.

Sun H, Li X, Dai S, Shen X, Qiu M Precis Clin Med. 2022; 4(3):209-214.

PMID: 35693217 PMC: 8982584. DOI: 10.1093/pcmedi/pbab017.

References

Barat S, Bozko P, Chen X, Scholta T, Hanert F, Gotze J . Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016; 55(12):2037-2050. DOI: 10.1002/mc.22449. View

Casadevall D, Gimeno J, Clave S, Taus A, Pijuan L, Arumi M . MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget. 2015; 6(18):16215-26. PMC: 4599265. DOI: 10.18632/oncotarget.3976. View

Lee S, Lee J, Sohn I, Mao M, Kai W, Park C . A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 2013; 33(11):5179-86. View

Jung K, Won Y, Kong H, Lee E . Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016. Cancer Res Treat. 2019; 51(2):417-430. PMC: 6473271. DOI: 10.4143/crt.2019.138. View

Li Y, Chen C, He Y, Cai S, Yang D, He W . Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012; 106(3):304-10. DOI: 10.1002/jso.23008. View

Sierra J, Tsao M . c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011; 3(1 Suppl):S21-35. PMC: 3225018. DOI: 10.1177/1758834011422557. View

Furge K, Zhang Y, Woude G . Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000; 19(49):5582-9. DOI: 10.1038/sj.onc.1203859. View

Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J . c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007; 98(7):1006-13. PMC: 11159971. DOI: 10.1111/j.1349-7006.2007.00493.x. View

Sharma A, Sharma K, Gupta A, Yadav A, Kumar A . Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World J Gastroenterol. 2017; 23(22):3978-3998. PMC: 5473118. DOI: 10.3748/wjg.v23.i22.3978. View

10.

Heo M, Kim H, Lee H, Kim K, Lee J, Park S . The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). J Cancer. 2017; 8(8):1395-1399. PMC: 5479244. DOI: 10.7150/jca.17898. View

11.

Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y . Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology. 1994; 20(5):1231-6. View

12.

Vigna E, Naldini L, Tamagnone L, Longati P, Bardelli A, Maina F . Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. Cell Mol Biol (Noisy-le-grand). 1994; 40(5):597-604. View

13.

Narayan R, Creasy J, Goldman D, Gonen M, Kandoth C, Kundra R . Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. Cancer. 2018; 125(4):575-585. PMC: 6636637. DOI: 10.1002/cncr.31850. View

14.

Schildhaus H, Heukamp L, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E . Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012; 25(11):1473-80. PMC: 4089812. DOI: 10.1038/modpathol.2012.102. View

15.

Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A . Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005; 206(3):356-65. DOI: 10.1002/path.1779. View

16.

Yang L, Guo T, Jiang S, Yang Z . Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 2011; 59(118):1769-75. DOI: 10.5754/hge11744. View

17.

Radaeva S, Ferreira-Gonzalez A, Sirica A . Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology. 1999; 29(5):1453-62. DOI: 10.1002/hep.510290524. View

18.

Blumenschein Jr G, Mills G, Gonzalez-Angulo A . Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012; 30(26):3287-96. PMC: 3434988. DOI: 10.1200/JCO.2011.40.3774. View

19.

Moon W, Park H, Lee H, Pai R, Tarnawski A, Kim K . Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat. 2009; 37(3):171-6. PMC: 2785404. DOI: 10.4143/crt.2005.37.3.171. View

20.

Ou S, Kwak E, Siwak-Tapp C, Dy J, Bergethon K, Clark J . Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011; 6(5):942-6. DOI: 10.1097/JTO.0b013e31821528d3. View